138 results about "Ophthalmic preparations" patented technology

The invention provides an eye drop composition as well as a preparation method and application thereof, and belongs to the technical field of ophthalmic preparations. The eye drop composition adopted by the invention is prepared from the following components: brimonidine tartrate, hyaluronic acid, collagen, trehalose and injection water. By compounding the components, the eye drops which can realize slow release of brimonidine tartrate and prolong the antihypertensive action time and have the characteristics of relieving blink discomfort, long-acting moisturizing, anti-inflammatory soothing, mildness, corrosion prevention and the like are prepared; the eye drops are beneficial to people suffering from glaucoma, intraocular hypertension, xerophthalmia, postoperative inflammation or allergy and preservative sensitivity or preservative allergy, the life quality is improved, and diseases are relieved.

A topical ophthalmological composition includes a muscarinic receptor antagonist as an active pharmaceutical ingredient; and medium chain triglycerides (MCTs) or light liquid paraffin oil as liquid vehicle. The topical ophthalmological composition treats an ocular disease.

The present invention relates to an ophthalmic preparation. The ophthalmic preparation comprises: penehyclidine hydrochloride, phosphate buffer, sodium chloride and hypromellose; wherein, based on the total volume of the ophthalmic preparation, the concentration of the phosphate buffer is not higher than 25 mM and not 0 mM, the mass-volume ratio of penehyclidine hydrochloride is 0.01% - 2%, and the mass ratio of penehyclidine hydrochloride to sodium chloride is (0.011 - 0.85):1. The ophthalmic preparation of the present invention has the advantages of low irritation and high stability.

The invention provides gelatin derivative microspheres coated with stem cell exosomes, a preparation method of the gelatin derivative microspheres and application of the gelatin derivative microspheres in preparation of external ophthalmic preparations, and relates to the technical field of medicines. The gelatin derivative microsphere mainly comprises a microsphere core and a shell, wherein the microsphere core is a stem cell exosome coated with a gelatin derivative; the shell is obtained by crosslinking a gelatin derivative and sodium hyaluronate. The gelatin derivative used in the invention not only has good compatibility with the stem cell exosome, but also has good dispersibility in tears or periorbital secretion after being prepared by crosslinking the gelatin derivative and sodium hyaluronate, so that the elimination of an eye protection mechanism to the microspheres can be reduced, and the slow release effect of the exosome can be improved; besides, the shell formed by the hyaluronic acid has a very good tackifying effect, so that the retention time of the gelatin derivative hyaluronic acid microspheres in eyes is prolonged, and the problem of burst release of the medicine is also avoided by virtue of the double-layer coated microsphere structure.

The invention provides pharmaceutical compositions comprising about 0.05 to 0.1% (w / v) cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions.

The invention relates to an ophthalmic composition in an aqueous solution form. The ophthalmic composition consists of cyclosporine, medium chain triglyceride, polyoxyethylene (40) hydrogenated castor oil, polyethylene glycol 400, glycerol, sodium acetate and water. The pH value of the ophthalmic composition is close to that of tears, and the ophthalmic composition is good in medication comfort and good in stability during storage.

A noninvasive ophthalmic formulation, comprising a chelator (such as EDTA and its salts), a transport enhancer (such as Methyl Sulfonyl Methane; MSM), a second permeation enhancer such as propylene glycol, a thickening agent such as hydroxyethyl cellulose (HEC) and a surfactant such as polysorbate 80, is provided. The novel combination of the ingredients unexpectedly and beneficially reduces symptoms associated with early-stage, age-related cataracts. Methods for treating cataracts with compositions of the invention and measurement of improved visual function by measuring contrast sensitivity (CS) are provided.

Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of a muscarinic antagonist or an ophthalmic agent for treatment of an ophthalmic disorder or condition in a preservative-free ophthalmic formulation. Further disclosed herein include an ophthalmic composition including a low concentration of a muscarinic antagonist or an ophthalmic agent and deuterated water. Also disclosed herein are methods of treating an ophthalmic condition or disease by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

The present application relates to an ophthalmic preparation and use thereof. Specifically, the present application relates to an ophthalmic preparation of pilocarpine and use thereof for treating eye diseases. The ophthalmic preparation of pilocarpine provided by the present application has the beneficial effects of good stability and less eye irritation.

The present invention relates to ophthalmic formulations in which a synergistic combination of three different types of disinfectants (a polybiguanide compound, a quaternary ammonium compound and an antifungal / anti-acanthamoeba compound), in particular a combination of polyhexamethylene biguanide, polyquaternium-1 and myristoylaminopropyl dimethylamine, high concentrations of hyaluronates are enabled to provide better comfort and support for corneal health without compromising antimicrobial efficacy. The novel ophthalmic formulations support the use of hyaluronates at concentrations greater than 7.5 times as high as currently commercially available multi-purpose disinfectants.

The invention discloses an ophthalmic preparation and application thereof. The ophthalmic preparation comprises a TNF alpha nano antibody, a protective agent, a thickening agent, a buffer solution and an optional surfactant, and pH lt is larger than or equal to 6.0 and smaller than or equal to 0; 7, 7; the protective agent is selected from at least one of trehalose, mannitol, arginine and glycine; the thickening agent is selected from any one of hydroxypropyl methyl cellulose, polyvinyl alcohol and sodium hyaluronate; the buffer solution is a phosphate buffer solution or a histidine buffer solution. The ophthalmic formulations are useful in the treatment of immune-mediated inflammatory ophthalmic diseases.

The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

The present invention relates to the field of therapy and drug delivery. More specifically, therapeutic methods and pharmaceutical compositions for treating disorders of blood-tissue barrier-protected organs that harbor substantial populations of postmittal neurons, such as organs derived from the neural tube, including the central nervous system and the eye. The disclosed methods and compositions involve topical administration of an effector component that targets intracellular biological targets to such organs, in combination with a saponin component that enhances the effective uptake of the effector component into cells and / or enhances the effective delivery of the effector component within cells where the biological target is present. For example, the effector component may be an oligonucleotide therapeutic that targets gene products associated with CNS and / or ocular disorders. Due to the cellular uptake stimulating and / or endosomal escape enhancing effects of the saponin component, the neuropharmaceuticals and ophthalmic compositions presented herein for topical administration to the CNS and / or eye, respectively, can be formulated with lower concentrations of the effector component and / or lower volumes, which provides safety benefits to neurons and patient comfort.

An ophthalmic composition for treating non-infectious inflammatory diseases. The ophthalmic composition comprises an active substance and an ophthalmic excipient, wherein the active substance is a JAK inhibitor; and the ophthalmic excipient comprises a pH buffer, an osmotic pressure regulator, a solubilizer, and water for injection. The ophthalmic composition is used for topical eye drop administration, is compatible and stable with eyes, can improve the bioavailability of the active substance in the ophthalmic composition, can be used for treating non-infectious inflammatory diseases, is less invasive, has small side effects, involves a simple production process, and is amenable to large-scale production.

The invention provides stable ophthalmic formulations, a unit dose containing such formulations, medical kits, and methods for making and using such formulations and unit doses to treat patients suffering from a disorder mediated by an αv integrin, such as diabetic retinopathy.

To provide an ophthalmic agent and an ophthalmic antibacterial agent that contain azithromycin and are administered in specific doses and dosage regimens for specific indications.SOLUTION: The present invention relates to an ophthalmic agent that contains azithromycin and ophthalmologically acceptable additives to prevent or treat one or more of a patient's blepharitis, hordeolum, and lacrimal pouchitis or to prevent the progression of the disease, the ophthalmic agent being applied to the patient twice daily for 2 days and then once daily for 12 days in an appropriate quantity once. The invention also relates to an ophthalmic antibacterial agent.SELECTED DRAWING: None

A noninvasive ophthalmic formulation, comprising a chelator (such as EDTA and its salts), a transport enhancer (such as Methyl Sulfonyl Methane; MSM), a second polyoxyalkylene permeation enhancer such as propylene glycol capable of enhancing permeation through lipid-thickened ocular membranes, a thickening agent such as hydroxyethyl cellulose (HEC) and a surfactant such as polysorbate 80, is provided. The novel combination of the ingredients unexpectedly and beneficially reduces symptoms associated with early-stage, age-related cataracts. Methods for treating cataracts with compositions of the invention and measurement of improved visual function by measuring contrast sensitivity (CS) are provided.

The present invention relates to ophthalmic formulations wherein a synergistic combination of three different classes of disinfectants (a multimeric biguanide compound, a quaternary ammonium compound and an antifungal / anti-acanthamoeba compound, in particular a combination of polyhexamethylene biguanide, Polyquaternium-1 and myristamidopropyl dimethylamine) enables the use of high concentrations of hyaluronate for providing better comfort and support of corneal health without compromising antimicrobial efficacy. The novel ophthalmic formulations support the use of more than 7.5 times higher concentrations of hyaluronate than are present in currently marketed multi-purpose disinfection solutions.

To provide a novel ophthalmic composition comprising diquafosol or a salt thereof.SOLUTION: There is provided an ophthalmic composition comprising diquafosol or a salt thereof and a cationic polymer, wherein the cationic polymer is at least one selected from the group consisting of chitosan, a chitosan derivative, a cationic (meth)acrylate copolymer, a cationic silicone polymer, a diallyl quaternary ammonium salt / acrylamide copolymer, cationic hydrolyzed keratin, cationic hydrolyzed silk, cationic hydrolyzed collagen, cationic hydrolyzed casein, cationic hydrolyzed soybean protein, a cationic vinylpyrrolidone copolymer, polyvinylpyrrolidone, homopolymers of dimethyl diacrylic ammonium chloride, an adipic acid / dimethylaminohydroxypropyl diethylenetriamine copolymer, an adipic acid / epoxy propyldiethylenetriamine copolymer and an acrylamide / β-methacroyloxyethyltrimethylammonium methyl sulfate copolymer.SELECTED DRAWING: None

To provide an ophthalmic formulation for treating or preventing glaucoma or pathogenic intraocular pressure.SOLUTION: The ophthalmic formulation comprises a Wnt receptor inhibitor that specifically inhibits expression of a Wnt receptor selected from among frizzled-2 (FZD2), frizzled-5 (FZD5), and receptor tyrosine kinase like orphan receptor 1 (ROR1) through genetic manipulation.SELECTED DRAWING: None

The present invention relates to a protein tyrosine kinase inhibitor and an ophthalmic preparation thereof. The protein tyrosine kinase inhibitor not only effectively antagonizes the activity of a VEGFR receptor tyrosine kinase, but also improves the pharmacokinetic properties thereof, while exhibiting high selectivity in inhibiting the activity of an "off-target" EGFR tyrosine kinase, thereby reducing or avoiding side effects, particularly those affecting the eyes. The preparation can greatly improve the solubility of the protein tyrosine kinase inhibitor compound, prolong the residence time of the compound on the ocular surface, increase exposure in fundus tissue, and improve the bioavailability.

A solubilizing composition for the poorly soluble drug rebamipide, its preparation method and application, and the solubilizing method, by combining rebamipide with a phosphorylated drug in a specific ratio, effectively improves the solubility of rebamipide in PBS. The solubilizing composition prepared by this invention significantly improves the bioavailability of rebamipide, providing a new approach for the development of oral and ophthalmic formulations of rebamipide.

The invention provides an animal ophthalmic preparation and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The animal ophthalmic preparation provided by the invention is prepared from the following components in percentage by mass: 0.1 to 5 percent of moxifloxacin hydrochloride nanoparticles coated with chitosan, 10 to 40 percent of poloxamer 188, 0.1 to 2 percent of osmotic pressure regulator and the balance of water for injection. According to the animal ophthalmic preparation provided by the invention, the moxifloxacin hydrochloride nanoparticles coated with chitosan are adopted, so that the moxifloxacin hydrochloride can be slowly released, and the drug effect is prolonged; the poloxamer 188 is added as the gel, can exist in a liquid form at a low critical solution temperature or below, and is gelatinized after the environment temperature is increased, so that the use comfort of the ophthalmic preparation is improved. Results of the embodiment show that the animal ophthalmic preparation provided by the invention is long in efficacy time and small in irritation.

Ophthalmic pharmaceutical formulations of the phosphodiesterase-4 inhibitor, roflumilast formulated with optimized viscosity and are suitable for intravitreal or other forms of ocular administration. The compositions can improve drug administration and absorption, distribution, metabolism, and excretion (ADME) properties. The ophthalmic pharmaceutical formulations can be administered via intravitreal injection resulting in the formation of a depot in the vitreous. The depot can remain in the vitreous for a prolonged period of time resulting in therapeutic drug levels over this period of time and improved durability.

The invention discloses a small-molecule active aldehyde scavenger-albumin coupling medicine as well as a preparation method and application of the small-molecule active aldehyde scavenger-albumin coupling medicine. The coupling drug comprises a) the small molecule active aldehyde scavenger compound or the derivative thereof and b) albumin, and the albumin comprises at least one of human serum albumin, recombinant albumin, bovine serum albumin, ovalbumin and mouse serum albumin. The medicine is further prepared into an ophthalmic preparation, the retention time of the medicine in the cornea is prolonged, the in-vitro active aldehyde removal efficiency of the medicine is improved to 1.5 times of that of NS-2, expression (larger than or equal to 50%) of a human corneal epithelial cell inflammatory factor IL-6 is remarkably inhibited, and irritation to eyes is avoided. Through the synergistic effect of long-acting slow release of the albumin carrier and targeted removal of NS, the technical defects that a traditional xerophthalmia medicine is short in effect and single in mechanism are overcome, and a definite clinical transformation value is achieved.

To provide an appropriate ophthalmic composition for treatment of dry eye syndrome using Tanfanercept.SOLUTION: Provided is an ophthalmic composition comprising Tanfanercept as an active ingredient for treating dry eye syndrome in a patient having moderate to severe dry eye.SELECTED DRAWING: Figure 26

To provide a novel ophthalmic composition. [Solution] The ophthalmic composition is composed of (A) one or more selected from the group consisting of pranoprofen and its salts, and (B) one or more selected from the group consisting of epinastine and its salts.

The invention relates to ophthalmic compositions comprising thiol drugs, such as cysteamine, for the prevention and / or treatment of ocular conditions related to the hardening and / or opacification of the crystalline lens of the eye; for instance, ocular conditions such as cataracts and presbyopia.